Elsevier

Blood Reviews

Volume 7, Issue 4, December 1993, Pages 229-242
Blood Reviews

Factor XIII: Inherited and acquired deficiency

https://doi.org/10.1016/0268-960X(93)90010-2Get rights and content

Abstract

Factor XIII (XIII), an enzyme found in plasma (present as a pro-enzyme), platelets and monocytes, is essential for normal haemostasis. It may also have a role to play in the processes of wound healing and tissue repair. Inherited XIII deficiency results in a life-long, severe bleeding diathesis which, if untreated, carries a very high risk of death in early life from intracranial bleeding. XIII is a zymogen requiring thrombin and calcium for activation. In plasma, XIII has two subunits: the ‘a’ subunit, which is the active enzyme, and the ‘b’ subunit which is a carrier protein. Activated XIII modifies the structure of clot by covalently crosslinking fibrin through an ε(γ-glutamyl)lysine link. It also crosslinks other proteins, including fibronectin and alpha-2-plasmin inhibitor (α-2PI), into the clot through the same link. Clot modified by XIII is physically stronger, relatively more resistant to fibrinolysis and may be a more suitable medium for the ingrowth of fibroblasts.

Inheritance of factor XIII is autosomal recessive. The majority of patients with the inherited defect show no XIII activity and absence of ‘a’ subunit protein in plasma, platelets and monocytes. At the molecular level, the defect is not a major gene rearrangement or deletion, but most likely a single point mutation which may be different in each family. Because of the severity of the bleeding diathesis, prophylaxis is desirable and has been shown to be very effective as the in vivo half-life of plasma XIII is long, and low plasma levels are sufficient for haemostatis. Acquired inhibitors have been reported in only two cases with inherited XIII deficiency.

Acquired XIII deficiency has been described in a variety of diseases and bleding has been controlled by therapy with large doses of XIII in such conditions as Henoch-Schönlein purpura, various forms of colitis, erosive gastritis and some forms of leukaemia. Large dose XIII therapy has also been used in an endeavour to promote wound healing after surgery and bone union in non-healing fractures. The use of XIII in these conditions remains controversial.

Very rarely a bleeding diathesis results from the development of a specific inhibitor to XIII arising de novo, often as a complication in the course of a disease or in association with long-term drug therapy. The bleeding diathesis in these patients is difficult to treat.

References (185)

  • A Mary et al.

    b-Chains prevent the proteolytic inactivation of the a-chains of plasma Factor XIII

    Biochim Biophys Acta

    (1988)
  • L Muszbek et al.

    FXIII of blood coagulation in human monocytes

    Thromb Res

    (1985)
  • J.E. Folk et al.

    The ε-(γ-glutamyl)lysine crosslink and the catalytic role of transglutaminases

    Adv Protein Chem

    (1977)
  • J McDonagh et al.

    Factor XIII deficiency: A genetic study of two affected kindreds in Finland

    Blood

    (1974)
  • S.I. Chung et al.

    Relationship of the catalytic properties of human plasma and platelet transglutaminase (activated blood coagulation factor XIII) to their subunit structure

    J Biol Chem

    (1974)
  • J Kroll

    The subunit composition of Factor XIII proteins in normal and Factor XIII deficiency plasma and serum by line immunoelectrophoresis

    Clin Chim Acta

    (1989)
  • R.L. Kradin et al.

    Factor XIII A is synthesized and expressed on the surface of U937 cells and alveolar macrophages

    Blood

    (1987)
  • J.A. Nagy et al.

    Biosynthesis of Factor XIII B subunit by human hepatoma cell lines

    Blood

    (1986)
  • G Barkan et al.

    Zur Frage der Reversibilitat der Fibringerinnung II

    Biochem Ztschr

    (1923)
  • J Mellanby et al.

    Calcium and blood coagulation

  • W.S. Tillett et al.

    The fibrinolytic activity of hemolytic streptococci

    J Exp Med

    (1933)
  • K.C. Robbins

    A study on the conversion of fibrinogen to fibrin

    Am J Physiol

    (1944)
  • K Laki et al.

    On the solubility of fibrin clots

    Science

    (1948)
  • L Lorand

    Fibrin clots. Some properties on the ‘serum factor’

    Nature

    (1950)
  • L Lorand

    Contributions to the fibrinogen fibrin problem. (Fibrin stabilizing factor — FSF)

  • K Buluk et al.

    O stabilizacji wloknika czyli trzeciej fazie fibrynogenezy

    Roczniki Akademii Medycznej

    (1955)
  • A.G. Lowey et al.

    Fibrinase. I. Purification of substrate and enzyme

    J Biol Chem

    (1961)
  • K Buluk et al.

    Conversion of fibrin to desmofibrin

    Nature

    (1961)
  • Loewy A G, Edsall J T. Studies on the formation of urea-insoluble fibrin. J Biol Chem 211:...
  • L Lorand et al.

    Specific inhibitors and the chemistry of fibrin polymerisation

    Biochem J

    (1964)
  • J.J. Pisano et al.

    ε(γ-glutamyl)lysine, crosslink of polymerised fibrin

    Thromb Diath Haemorr

    (1970)
  • P.A. McKee et al.

    Subunit structure of human fibrinogen, soluble fibrin and crosslinked insoluble fibrin

  • J.S. Finlayson et al.

    Crosslinking of rabbit fibrin in vivo

    Thromb Diath Haemorr

    (1974)
  • H.W.J. Harding et al.

    Formation of the ε(γ-glutamyl)lysine crosslink in hair proteins. Investigation of transamidases in hair follicles

    Biochemistry

    (1972)
  • R.S. Asquith et al.

    The identification of εN-(γ-glutamyl)-l-lysine crosslinks in native wool keratins

    Biochim Biophys Acta

    (1970)
  • P Henriksson et al.

    Factor XIII activation and interactions

  • L Shen et al.

    Contribution of fibrin stabilization to clot strength

    J Clin Invest

    (1983)
  • L Lorand et al.

    Accelerated lysis of blood clots

    Nature

    (1962)
  • F Duckert et al.

    A hitherto undescribed congenital haemorrhagic diathesis probably due to fibrin stabilising factor deficiency

    Thromb Diath Haemorr

    (1960)
  • L Lorand et al.

    Human factor XIII: Fibrin-Stabilizing Factor

  • K.J.A. Miloszewski et al.

    Fibrin stabilisation and factor XIII deficiency

  • S.L. Abbondanzo et al.

    Intracranial hemorrhage in congenital deficiency of Factor XIII

    Am J Pediatr Hematol Oncol

    (1988)
  • V.M. Shashidhar et al.

    Congenital Factor XIII deficiency: a case report and review of literature

    Indian J Pathol Microbiol

    (1989)
  • V Thavaraj et al.

    Congenital Factor XIII deficiency. A family report

    Haematologia

    (1991)
  • J.E. Gootenberg et al.

    Clinical aspects of congenital coagulation Factor XIII deficiency

    Biomed Prog

    (1992)
  • S Lopaciuk

    Experience in the long term prophylactic therapy of four patients with congenital Factor XIII deficiency

  • R.A. de Vreker

    Fibrin stabilizing factor (FSF)

    Thromb Diath Haemorr

    (1964)
  • P.G. Board

    Genetic polymorphism of the A subunit of human coagulation factor XIII

    Am J Hum Genet

    (1979)
  • P.G. Board

    Genetic polymorphism of the B subunit of human coagulation factor XIII

    Am J Hum Genet

    (1980)
  • Yorifuji H, Anderson K, Lynch G W, Van de Water L, McDonagh J. B protein of Factor XIII: Differentiation between free B...
  • Cited by (0)

    View full text